Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.34 USD | +6.38% | +3.01% | -43.34% |
Business Summary
Number of employees: 94
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Monoclonal Antibody
100.0
%
| 2 | 100.0 % | 0 | 100.0 % | -82.28% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 2 | 100.0 % | 0 | 100.0 % | -82.28% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 23-10-29 |
Seth Harmon
DFI | Director of Finance/CFO | 45 | 23-04-30 |
Thomas Ciulla
CTO | Chief Tech/Sci/R&D Officer | 59 | 22-12-31 |
Thomas Beetham
COO | Chief Operating Officer | 55 | 23-10-29 |
Angela Sheen
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
Shan Wu
PRN | Corporate Officer/Principal | - | 23-10-29 |
Vahe Bedian
PRN | Corporate Officer/Principal | - | 20-10-27 |
Anthony Casciano
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Arlene Morris
BRD | Director/Board Member | 72 | 18-01-02 |
Tomas Kiselak
CHM | Chairman | 37 | 20-10-27 |
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 23-10-29 |
Peter Harwin
BRD | Director/Board Member | 38 | 20-10-27 |
Jennifer Moses
BRD | Director/Board Member | 49 | 21-07-13 |
Sarah Gheuens
BRD | Director/Board Member | 45 | 23-09-24 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 157,435 | 0 | 0 | 94.26 % |
Stock B | 0 | 143,522 | 0 | 0 | |
Stock C | 1 | 63,822,468 | 60,160,266 ( 94.26 %) | 0 |
Company contact information
Viridian Therapeutics, Inc.
221 Crescent Street Suite 401
02453, Waltham
+
http://www.viridiantherapeutics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.34% | 740M | |
+55.70% | 55.7B | |
+41.08% | 39.91B | |
-5.39% | 39.57B | |
-5.56% | 28.16B | |
+16.46% | 26.3B | |
-20.56% | 18.94B | |
+33.03% | 12.17B | |
+25.85% | 12.12B | |
+2.72% | 12.12B |
- Stock Market
- Equities
- VRDN Stock
- Company Viridian Therapeutics, Inc.